公开(公告)号：US20250134858A1

公开(公告)日：2025-05-01

申请号：US18836268

申请日：2023-02-10

Applicant: EpicentRx, Inc.

Inventor： Scott CAROEN ,  Tony REID ,  Bryan ORONSKY

IPC: A61K31/397 ,  A61K31/155 ,  A61K31/355 ,  A61K31/465 ,  A61K31/616 ,  A61K31/7088 ,  A61K35/14 ,  A61K35/18 ,  A61K36/062 ,  A61K39/395 ,  A61K45/06 ,  A61P1/16

Abstract: Compositions and methods for preventing or treating a disease or a disorder associated with dyslipidemia are provided. This includes prevention or treatment of non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH). The method comprises administering an effective amount of RRx-001, or a pharmaceutically acceptable salt thereof, to the subject in need thereof to reduce at least one factor of the disease or the disorder, such as a hepatic steatosis score, a serum ALT level, a fibrosis marker, a serum AST level, a hepatic level of cholesterol, a hepatic level of triglycerides, insulin resistance, hyperinsulinemia, a serum NLRP3 level, an oxidative or inflammatory stress marker in the subject, and/or a marker associated with low-density lipoprotein (LDL). In some embodiments, the effective amount of RRx-001, or the pharmaceutically acceptable salt thereof, is administered in a pharmaceutical composition that includes a blood product and/or an agent.